Tumor Necrosis Factor-alpha
"Tumor Necrosis Factor-alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.
| Descriptor ID |
D014409
|
| MeSH Number(s) |
D12.644.276.374.500.800 D12.644.276.374.750.626 D12.776.124.900 D12.776.395.930 D12.776.467.374.500.800 D12.776.467.374.750.626 D23.529.374.500.800 D23.529.374.750.626
|
| Concept/Terms |
Tumor Necrosis Factor-alpha- Tumor Necrosis Factor-alpha
- Tumor Necrosis Factor alpha
- Cachectin
- Cachectin-Tumor Necrosis Factor
- Cachectin Tumor Necrosis Factor
- Tumor Necrosis Factor Ligand Superfamily Member 2
- Tumor Necrosis Factor
- TNF Superfamily, Member 2
- TNFalpha
- TNF-alpha
|
Below are MeSH descriptors whose meaning is more general than "Tumor Necrosis Factor-alpha".
Below are MeSH descriptors whose meaning is more specific than "Tumor Necrosis Factor-alpha".
This graph shows the total number of publications written about "Tumor Necrosis Factor-alpha" by people in this website by year, and whether "Tumor Necrosis Factor-alpha" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 6 | 4 | 10 |
| 1995 | 11 | 6 | 17 |
| 1996 | 6 | 3 | 9 |
| 1997 | 4 | 5 | 9 |
| 1998 | 2 | 7 | 9 |
| 1999 | 3 | 11 | 14 |
| 2000 | 4 | 7 | 11 |
| 2001 | 10 | 9 | 19 |
| 2002 | 15 | 9 | 24 |
| 2003 | 11 | 12 | 23 |
| 2004 | 18 | 14 | 32 |
| 2005 | 8 | 10 | 18 |
| 2006 | 11 | 14 | 25 |
| 2007 | 15 | 17 | 32 |
| 2008 | 5 | 14 | 19 |
| 2009 | 10 | 12 | 22 |
| 2010 | 8 | 13 | 21 |
| 2011 | 7 | 15 | 22 |
| 2012 | 9 | 18 | 27 |
| 2013 | 11 | 6 | 17 |
| 2014 | 5 | 11 | 16 |
| 2015 | 6 | 14 | 20 |
| 2016 | 2 | 8 | 10 |
| 2017 | 6 | 10 | 16 |
| 2018 | 5 | 8 | 13 |
| 2019 | 3 | 8 | 11 |
| 2020 | 2 | 10 | 12 |
| 2021 | 0 | 8 | 8 |
| 2022 | 0 | 5 | 5 |
| 2023 | 1 | 6 | 7 |
| 2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Necrosis Factor-alpha" by people in Profiles.
-
Sequencing of Targeted Therapy in Psoriasis: Does it Matter? Am J Clin Dermatol. 2024 Sep; 25(5):795-810.
-
Some Drugs Have Two Faces: Paradoxical Colitis in a Patient with Psoriatic Arthritis Previously Treated with Etanercept and IL-17 Inhibitors. Dig Dis Sci. 2024 May; 69(5):1602-1607.
-
A pairwise cytokine code explains the organism-wide response to sepsis. Nat Immunol. 2024 Feb; 25(2):226-239.
-
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases. Adv Ther. 2024 02; 41(2):509-533.
-
Luteolin prevents TNF-a-induced NF-?B activation and ROS production in cultured human placental explants and endothelial cells. Placenta. 2024 01; 145:65-71.
-
Duration-sensitive association between air pollution exposure and changes in cardiometabolic biomarkers: Evidence from a predominantly African American cohort. Environ Res. 2024 Jan 01; 240(Pt 2):117496.
-
Identification of TNFa-mediated inflammation as potential pathological marker and therapeutic target for calcification progress of congenital bicuspid aortic valve. Eur J Pharmacol. 2023 Jul 15; 951:175783.
-
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. Ann Rheum Dis. 2023 07; 82(7):920-926.
-
Plasma and cerebrospinal fluid inflammatory markers and human aggression. Neuropsychopharmacology. 2023 06; 48(7):1060-1066.
-
Histotripsy induces apoptosis and reduces hypoxia in a neuroblastoma xenograft model. Int J Hyperthermia. 2023; 40(1):2222941.